Get the Daily Brief
Latest Biotech News
Novo pays up to $2.1B — grab for Omeros’ MASP‑3 antibody
Novo Nordisk agreed to acquire global rights to Omeros’ MASP‑3–blocking antibody zaltenibart for up to $2.1 billion plus sales royalties, paying roughly $340 million up front and near‑term...
Kite and Pregene... a $1.64B bet on in‑vivo CAR‑T
Gilead’s Kite Pharma signed a licensing and research deal with Chinese biotech Pregene Biopharma worth up to $1.64 billion, paying $120 million upfront to accelerate in‑vivo CAR‑T development. The...
Tubulis smashes record — €308M Series C to scale clinical ADC program
German ADC specialist Tubulis closed a €308 million (about $356 million) Series C, the largest private European raise focused on antibody‑drug conjugates to date. The financing positions the...
Adcytherix raises €105M Series A to advance ADC candidate
French antibody biotech Adcytherix secured €105 million (roughly $122 million) in a Series A to move its lead ADC program into clinical development next year. The financing aims to support...
Plasmidsaurus launches ultrafast RNA‑seq service — results in days
Plasmidsaurus introduced an ultrafast RNA‑seq service for Illumina short‑read applications, promising fully analyzed transcriptomics data in as little as three days from crude cell preps. The...
Pelage raises $120M to fund Phase III for hair follicle stem‑cell therapy
Regenerative medicine firm Pelage Pharmaceuticals closed a $120 million Series B co‑led by ARCH Venture Partners and GV to advance PP405, a topical small molecule designed to reactivate dormant...
Praxis clears two Phase 3 trials: ulixacaltamide heads for NDA
Praxis Precision Medicines reported that its oral small molecule ulixacaltamide met primary endpoints in two pivotal Phase 3 trials for essential tremor. The company said the dual wins support...
Novo wagers up to $2.1B on Omeros’ MASP‑3 antibody: zaltenibart deal
Novo Nordisk agreed to acquire global rights to Omeros’ MASP‑3 antibody zaltenibart in a deal worth up to $2.1 billion, with near-term payments and royalties. Novo said it will launch Phase 3...
Kite inks in vivo CAR‑T pact with Pregene: up to $1.64B
Gilead’s Kite Pharma signed a licensing and collaboration deal with China’s Pregene Biopharma to accelerate development of in vivo CAR‑T therapies, with reported value up to $1.64 billion and an...
Roche buys Hansoh’s CDH17 ADC rights: $80M upfront, $1.45B milestones
Roche agreed to acquire global rights to Hansoh Pharma’s early‑stage antibody‑drug conjugate targeting CDH17 in colorectal cancer, paying $80 million upfront and up to $1.45 billion in milestones....
Pelage raises $120M Series B — moves PP405 toward Phase III
Pelage Pharmaceuticals closed a $120 million Series B co‑led by ARCH Venture Partners and GV to advance PP405, a topical small molecule that aims to reactivate dormant hair‑follicle stem cells,...
Tubulis smashes European record: €308M Series C to scale ADC program
Tubulis GmbH secured an oversubscribed €308 million (about $356 million) Series C—the largest private ADC‑focused Series C in Europe—to accelerate clinical development of its lead ADC TUB‑040 and...
DeepSomatic and CASTLE: AI caller and benchmarks advance somatic calling
Two Nature Biotechnology reports detail major advances in somatic‑variant detection: DeepSomatic, a deep‑learning somatic small‑variant caller that works across short‑ and long‑read platforms, and...
Tumor‑on‑chip models map CAR‑T failures and fixes: vascularized human explants
Two independent reports introduced vascularized tumor‑on‑chip platforms that model human solid tumors and permit controlled CAR‑T perfusion, visualization, and functional testing. Authors used...
Google’s C2S‑Scale AI: model proposes and labs validate a cancer hypothesis
Google’s C2S‑Scale 27B foundation model, developed with Yale and based on Gemma, generated an in silico hypothesis for a drug acting as an interferon‑conditional amplifier of antigen presentation;...
In vivo programming momentum: Create Medicines rebrands; LNP startup raises seed
Two commercial moves signaled accelerating activity in in‑vivo immune programming. Myeloid Therapeutics rebranded as Create Medicines and broadened its platform from myeloid programming to include...
Pelage raises $120m Series B — pushes topical stem‑cell hair therapy to Phase III
Pelage Pharmaceuticals closed a $120 million Series B led by ARCH Venture Partners and GV to advance PP405, a topical small molecule designed to reactivate dormant hair‑follicle stem cells, into...
Praxis’ tremor pill hits Phase 3 goals — shares surge
Praxis Precision Medicines reported that ulixacaltamide met primary endpoints in two pivotal Phase 3 trials for essential tremor, prompting plans to prepare an NDA and sending the stock sharply...
Kite doubles down on in‑vivo CAR‑T — $1.6B pact with Pregene to accelerate injectables
Gilead’s Kite Pharma signed a pair of strategic agreements with Shenzhen‑based Pregene Biopharma worth up to roughly $1.6–1.64 billion to accelerate in‑vivo CAR‑T development, paying an upfront...
Novo buys Omeros’ MASP‑3 antibody — $340m up front, $2.1B upside
Novo Nordisk agreed to acquire global rights to Omeros’ zaltenibart (OMS‑906), an antibody targeting MASP‑3 in the complement cascade, in a deal structured for $340 million up front and up to $2.1...